Physician profile
Michael D Render
NPI 1134679129
$3,904.66
in general payments reported to CMS, 2019-2025
23 companies · $911 in 2025
The $911 reported for 2025 was more than what 82% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,422 · 2022: $262 · 2023: $651 · 2024: $659 · 2025: $911.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,122 · Education: $98.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,122.04 |
| Education | $98.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $856.94 | 2021-2025 | |
| Dermavant Sciences, INC. | $492.20 | 2023-2024 | Vtama |
| Amgen INC. | $354.82 | 2021-2023 | Otezla |
| Janssen Biotech, INC. | $332.90 | 2021-2025 | Tremfya, Simponi Aria |
| Ucb, INC. | $236.58 | 2021-2025 | Bimzelx |
| Sun Pharmaceutical Industries INC. | $197.21 | 2021 | |
| Organon LLC | $184.39 | 2025 | Vtama |
| Novartis Pharmaceuticals Corporation | $182.20 | 2021-2023 | |
| Lilly USA, LLC | $162.01 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $149.10 | 2021-2025 | Dupixent |
| Genzyme Corporation | $141.49 | 2021-2025 | |
| Leo Pharma INC. | $108.12 | 2021-2024 | Adbry |
| Verrica Pharmaceuticals INC. | $91.69 | 2024 | Ycanth |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $75.84 | 2021-2023 | Arazlo, Jublia |
| Incyte Corporation | $70.53 | 2021-2025 | Opzelura |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $58.13 | 2024 | Zoryve |
| Vyne Pharmaceuticals INC. | $51.96 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $51.39 | 2023-2024 | Sotyktu |
| Epi Health, LLC | $35.84 | 2021 | |
| Organogenesis INC. | $26.05 | 2022 | |
| Kyowa Kirin, INC. | $18.43 | 2021 | |
| Pfizer INC. | $15.27 | 2025 | |
| Almirall LLC | $11.57 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Render listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.